BRPI0408876A - derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer - Google Patents

derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer

Info

Publication number
BRPI0408876A
BRPI0408876A BRPI0408876-0A BRPI0408876A BRPI0408876A BR PI0408876 A BRPI0408876 A BR PI0408876A BR PI0408876 A BRPI0408876 A BR PI0408876A BR PI0408876 A BRPI0408876 A BR PI0408876A
Authority
BR
Brazil
Prior art keywords
treating
substituted
unsubstituted
tumor
indazole derivative
Prior art date
Application number
BRPI0408876-0A
Other languages
English (en)
Inventor
Yoshihisa Ohta
Fumihiko Kanai
Shinji Nara
Yutaka Kanda
Hiroshi Umehara
Yukimasa Shiotsu
Tomoki Naoe
Hitoshi Kiyoi
Keiko Kawashima
Hiromi Ando
Motoki Miyama
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of BRPI0408876A publication Critical patent/BRPI0408876A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADO DE INDAZOL, COMPOSIçãO FARMACêUTICA, AGENTES ANTI-TUMORAL E TERAPêUTICO, USO DO DERIVADO DE INDAZOL OU DO SEU SAL FARMACEUTICAMENTE ACEITáVEL, E, MéTODOS PARA TRATAR DE TUMOR, PARA TRATAR DE LEUCEMIA, PARA TRATAR DE MIELOMA OU LINFOMA, PARA TRATAR DE CARCINOMA SóLIDO E PARA TRATAR DE CáNCER". Derivados de indazol representados pela fórmula geral (I) ou seus sais farmacologicamente aceitáveis: (I) em que R¬ 1¬ é CONR¬ 1a¬R¬ 1b¬ (R¬ 1a¬ e R¬ 1b¬ São , cada um independentemente, hidrogênio, alquila inferior, arila, aralquila ou um grupo heterocíclico, ou R¬ 1a¬ e R¬ 1b¬ juntos com o átomo de nitrogênio adjacente podem formar um grupo heterocíclico) ou coisa parecida; e R¬ 2¬ é hidrogênio, CONR¬ 2a¬R¬ 2b¬ (em que R¬ 2a¬ e R¬ 2b¬ São como definido para R¬ 1a¬ e R¬ 1b¬), NR¬ 2c¬R¬ 2d¬ (em que R¬ 2c¬ e R¬ 2d¬ São, cada um independentemente, hidrogênio, alquila inferior, alcanoíla inferior, aroíla, heteroaroíla, aralquila, alquilsulfonila ou arilsulfonila) ou coisa parecida.
BRPI0408876-0A 2003-07-30 2004-07-30 derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer BRPI0408876A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003203508 2003-07-30
PCT/JP2004/011287 WO2005012257A1 (ja) 2003-07-30 2004-07-30 インダゾール誘導体

Publications (1)

Publication Number Publication Date
BRPI0408876A true BRPI0408876A (pt) 2006-04-11

Family

ID=34113614

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408876-0A BRPI0408876A (pt) 2003-07-30 2004-07-30 derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer

Country Status (15)

Country Link
US (2) US7470717B2 (pt)
EP (1) EP1652842B1 (pt)
JP (1) JP4335212B2 (pt)
KR (1) KR20060119705A (pt)
CN (1) CN100390149C (pt)
AT (1) ATE553092T1 (pt)
AU (1) AU2004260756B2 (pt)
BR (1) BRPI0408876A (pt)
CA (1) CA2518950A1 (pt)
EA (1) EA010165B1 (pt)
ES (1) ES2384568T3 (pt)
MX (1) MXPA05011420A (pt)
NO (1) NO20055333L (pt)
WO (1) WO2005012257A1 (pt)
ZA (1) ZA200509952B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040805A2 (en) 2002-03-13 2005-04-30 Janssen Pharmaceutica N.V. Carbonylamino derivatives as novel inhibitors histone deacetylase
EA007099B1 (ru) 2002-03-13 2006-06-30 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
CA2475766C (en) 2002-03-13 2012-06-05 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
MXPA04008797A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
AU2004260756B2 (en) * 2003-07-30 2010-03-25 Kyowa Hakko Kirin Co., Ltd. Indazole derivatives
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
ES2426482T3 (es) * 2005-01-27 2013-10-23 Kyowa Hakko Kirin Co., Ltd. Inhibidor de IGF-1R
US7759491B2 (en) * 2005-04-28 2010-07-20 Kyowa Hakko Kirin Co., Ltd. Method for producing indazol-3-ylmethyl phosphonium salt
ES2553178T3 (es) 2005-05-18 2015-12-04 Janssen Pharmaceutica N.V. Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa
JP5070214B2 (ja) * 2005-10-27 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの阻害剤としてのスクエア酸誘導体
WO2007082874A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007082876A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP1981875B1 (en) 2006-01-19 2014-04-16 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
CA2631876C (en) 2006-01-19 2014-05-27 Janssen Pharmaceutica N.V. Aminophenyl derivatives as inhibitors of histone deacetylase
US20120329794A1 (en) 2006-06-30 2012-12-27 Kyowa Hakko Kirin Co., Ltd. Ab1 KINASE INHIBITORS
EP2036894A4 (en) * 2006-06-30 2011-01-12 Kyowa Hakko Kirin Co Ltd AURORA INHIBITOR
JPWO2008020606A1 (ja) * 2006-08-16 2010-01-07 協和発酵キリン株式会社 血管新生阻害剤
GB0619325D0 (en) 2006-09-30 2006-11-08 Univ Strathclyde New compounds
JPWO2008108386A1 (ja) 2007-03-05 2010-06-17 協和発酵キリン株式会社 医薬組成物
EP2133095A4 (en) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd PHARMACEUTICAL COMPOSITION
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
WO2009143404A1 (en) * 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
CN103804382A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103804306A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019051396A1 (en) * 2017-09-08 2019-03-14 President And Fellows Of Harvard College SMALL MOLECULE INHIBITORS OF EBOLA VIRUSES AND LASSA FEVER, AND METHODS OF USE THEREOF
JP7434274B2 (ja) * 2018-07-23 2024-02-20 セルジーン・クオンティセル・リサーチ・インコーポレイテッド ブロモドメイン阻害剤の合成方法
WO2024052685A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232059A (ja) 1988-07-18 1990-02-01 Kyowa Hakko Kogyo Co Ltd インダゾール誘導体
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7238853B2 (en) * 2000-07-14 2007-07-03 Unicrop Ltd Molecular mechanisms for gene containment in plants
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
US7429609B2 (en) * 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
EP1582211A1 (en) * 2002-12-03 2005-10-05 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
AU2004260756B2 (en) * 2003-07-30 2010-03-25 Kyowa Hakko Kirin Co., Ltd. Indazole derivatives

Also Published As

Publication number Publication date
EP1652842A4 (en) 2008-10-01
ATE553092T1 (de) 2012-04-15
MXPA05011420A (es) 2005-12-12
ES2384568T3 (es) 2012-07-09
ZA200509952B (en) 2006-09-27
AU2004260756A1 (en) 2005-02-10
CN1777590A (zh) 2006-05-24
CN100390149C (zh) 2008-05-28
KR20060119705A (ko) 2006-11-24
EA200600333A1 (ru) 2006-06-30
JP4335212B2 (ja) 2009-09-30
NO20055333L (no) 2005-11-11
EP1652842B1 (en) 2012-04-11
US20090082348A1 (en) 2009-03-26
JPWO2005012257A1 (ja) 2006-09-14
EP1652842A1 (en) 2006-05-03
CA2518950A1 (en) 2005-02-10
AU2004260756B2 (en) 2010-03-25
US20070117856A1 (en) 2007-05-24
US7919517B2 (en) 2011-04-05
WO2005012257A1 (ja) 2005-02-10
EA010165B1 (ru) 2008-06-30
US7470717B2 (en) 2008-12-30

Similar Documents

Publication Publication Date Title
BRPI0408876A (pt) derivado de indazol, composição farmacêutica, agentes anti-tumoral e terapêutico, uso do derivado de indazol ou do seu sal farmaceuticamente aceitável, e, métodos para tratar de tumor, para tratar de leucemia, para tratar de mieloma ou linfoma, para tratar de carcinoma sólido e para tratar de cáncer
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
UY25344A1 (es) Procedimiento para la preparacion de derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
DE602004023838D1 (de) Hemmer der akt aktivität
DE602004026047D1 (de) Hemmer der akt aktivität
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CY1110631T1 (el) Διαλυτοποιημενα δηλητηρια τοποϊσομερασης
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
CA2389545A1 (en) Chemokine receptor binding heterocyclic compounds
EP1643984A4 (en) USE OF PARTHENOLID DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS
NO20055655D0 (no) Anvendelse av azetidinkarboksamidderivater i terapi
RU2003137007A (ru) Новые пиридилцианогуанидиновые соединения
DK1056704T3 (da) Antitumormidler
ATE390923T1 (de) Topoisomerase-giftmittel
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
EA200701780A1 (ru) Противоопухолевое средство
DE60231426D1 (de) Solubilisierte topoisomerase-gift-mittel
PE20060380A1 (es) Derivados de pirido-pirimidina en la prevencion y tratamiento de la proliferacion celular
JP2005531563A5 (pt)
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
BRPI0414778A (pt) 6-aril-7-halo-imidazo[1,2-a]pirimidinas como agentes anticáncer
TH41250A (th) อนุพันธ์ของ 5-แนฟธาลีน-1-อิล-1,3-ไดออกเซน การเตรียมและประโยชน์ทางการรักษาของสารดังกล่าว

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP)

Free format text: NOME ALTERADO DE: KYOWA HAKKO KOGYO CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.